This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Thus, the researchers aimed to determine prospectively whether 18F-FES PET improves staging for patients with clinical stage II/III or local-regional recurrent, grade 1 or 2, ER-positive breast cancer compared with standard F-18 FDG-PET. All lesions had also been identified at mammography and MRI.
Alzheimer’s disease patients with cognitive impairment or dementia who were referred for amyloid PETscans had fewer hospitalizations compared with a matched control group, according to a study published October 9 in JAMA Neurology. Each participant was matched to a control Medicare beneficiary who had not undergone amyloid PET.
F-18 fluoroestradiol (FES)-PETscans can predict whether or not endocrine therapy may be effective in women with estrogen receptor (ER)-positive breast cancer, according to a study published March 13 in the Journal of Nuclear Medicine. A visual abstract of the analysis. Image courtesy of the Journal of Nuclear Medicine.
Men should have prostate-specific membrane antigen (PSMA) PETscans about eight months after undergoing external beam radiotherapy for prostate cancer, a group at the University of California, Los Angeles has reported. The median duration between the first PETscan and the end-date of radiotherapy was 2.3
The finding is from an analysis of 300 participants who underwent multiple F-18 flortaucipir tau PETscans between 2015 and 2022 and suggests depression could be a modifiable risk factor for the disease, noted lead author Daniel Talmasov, MD, and colleagues.
F-18 florbetaben PETscans for diagnosing Alzheimer’s disease can be reduced from 20 minutes to five minutes without losing accuracy, according to a recent study. Our findings suggest that shorter scan times are a viable and effective option for brain amyloid PET imaging in clinical settings,” the group wrote.
Similar to F-18 FDG-PET, the technique targets glucose metabolism specifically its downstream metabolites, lactate (Lac), glutamate and glutamine (Glx), which function abnormally in Alzheimers disease. Given that PETscans are more expensive and expose patients to small amounts of radiation, DMI is being explored as an alternative.
In a study published April 17 in Clinical Nuclear Medicine , the group at Brigham tested a new TSPO radiotracer they developed for visualizing such activity called F-18 PBR06. The researchers performed F-18 PBR06 PETscans on 22 patients with MS and eight healthy controls. Image courtesy of Clinical Nuclear Medicine.
Patients with less tau pathology on PETscans may respond better to treatment with the new Alzheimer’s disease drug donanemab, according to an October 25 news report in the journal Practical Neurology. Research suggests that the accumulation of these proteins is a continuous process that starts decades before the onset of symptoms.
Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. The clinical utility of amyloid PETscans has been systematically studied in many other countries.
A group in France has offered an explanation for long COVID brain fog, with the concept based on a visual brain pattern they discovered on patient PETscans, according to a study published October 13 in Medical Hypotheses. “We A) PETscan of a healthy subject. (B) B) PETscan of a long COVID patient.
Jacob Dubroff, MD, PhD, of the University of Pennsylvania in Philadelphia, provided evidence using carbon-11 (C-11) carfentanil PET that individual buprenorphine-treated patients have lower mu-opioid receptor activity across all brain regions than either methadone-treated patients or healthy controls.
PETscans have revealed specific brain pathology that may drive sleep disturbances in Alzheimer’s disease patients, according to a study published February 8 in the Journal of the Neurological Sciences. Nonetheless, the results have several implications for clinical practice, they wrote.
The findings were published in Clinical Nuclear Medicine. The newly published study involved performing PETscans on 22 people with MS and eight healthy controls. Those being treated with low-efficacy treatments had more abnormalities on their PETscans, suggesting more microglial cell activation.
Early brain accumulation of amyloid plaque on PETscans is associated with emerging depressive symptoms in cognitively unimpaired older adults, according to a study published August 29 in JAMA Network Open. The mean follow-up period was 8.6 The full study is available here.
According to clinical trials, amyloid PETscans showed that donanemab reduced amyloid plaques by up to 84% after 18 months of treatment. Donanemab is a monoclonal antibody that targets and clears beta-amyloid protein in the brain.
The group analyzed flortaucipir (Tauvid, Avid Pharmaceuticals) PETscans acquired over a 3.5-year Participants were clinically unimpaired and between ages 51 and 89 at the beginning of the study. The researchers aimed to investigate whether menopausal HT use is associated with later-life tau accumulation.
PET imaging has revealed brain pathology linked to faster clinical progression of Alzheimer’s disease in patients with ApoE4 gene variants, according to a study published November 6 in JAMA Neurology.
In small studies, F-18 PSMA-1007 PET/CT has shown promise as a more accurate approach based on its ability to reveal prostate-specific membrane antigen (PSMA) on the surface of cancer cells. In this phase II clinical trial, the researchers sought to evaluate the approach further.
Dynamic PETscans acquired in half the time of normal scans appear clinically feasible for patients with lung lesions, according to nuclear medicine researchers in Shenzhen, China. A 60-year-old male patient with clinical suspicion of lung cancer. The article was published March 5 in EJNMMI Physics.
F-18 FDG-PET is an established approach for diagnosing inflammation based on its ability to visualize increased cellular glucose metabolism, and the researchers hypothesized that it could be useful in patients with neurosarcoidosis. In all three cases, gadolinium-enhanced MRI scans did not show abnormalities.
They wrote that in their daily clinical practice, for instance, they promote voluntary coughing in dysphagic patients using a procedure called “cough‐inducing method with tartaric acid” (CiTA). In this study, the researchers evaluated whether the experimental PET system could clarify brain activity during CiTA.
PETscans typically used for diagnosing prostate cancer may have value in detecting inflammatory bowel disease (IBD), according to a case series published December 8 in Clinical and Experimental Gastroenterology. D) Axial F-18 DCFPyL PET/CT fusion imaging identifying active inflammation in the descending colon.
“Our results suggest that supplemental Ga-68 FAPI-46 PET may improve the noninvasive assessment of primary pulmonary lesions compared with F-18 FDG-PET and CT alone,” wrote lead author Manuel Röhrich, MD, and colleagues. This “markedly hampers” the assessment of single pulmonary lesions, the authors wrote.
The finding comes from a group at the Leuven Brain Institute in Leuven, Belgium, who compared tau PET/MRI brain scans among participants with late-life depression, mild cognitive impairment (MCI) due to Alzheimer’s disease, and nondepressed older adults.
A better understanding of the association between depressive symptoms and amyloid pathology will strengthen clinical diagnostics and prognosis and is essential for further therapeutic research, the group wrote. The study was published January 22 in JAMA Psychiatry.
Clinical brain imaging with a newly developed portable PET scanner appears feasible, with a comparison to conventional PET imaging for the first time revealing similar results in human subjects, according to a group in New York City. A link to the full study can be found here.
Mayo Clinic, Jacksonville, FL MOST SIGNIFICANT NEWS EVENT IN RADIOLOGY 1. Increased use of medical imaging by other specialties (turf battles) HOTTEST CLINICAL PROCEDURE 1. Hybrid CT/PETscanning 2. Weber State University, Ogden, UT 2. Introduction of 16-slice CT scanners 2. Ongoing shortage of qualified staff 2.
One potential application of fill-state data could be to serve as a readout for clinical trials, pending proof of longitudinal efficacy, the researchers added. If these challenges are successfully addressed, fill states may become a valuable tool for the diagnosis and staging of AD in PET imaging, Yun and Kim concluded.
Dr. Timothy Cloughesy, professor of neuro-oncology at the David Geffen School of Medicine at UCLA, is the senior author of abstract LBA1 , which highlights INDIGO clinical trial results, a global, randomized double-blinded, phase 3 study of vorasidenib verse placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
For instance, while the FDA advises that selection of patients for treatment be made using an approved PSMA radiotracer and based on tracer uptake in tumors, they found that most commonly, subjective visual whole-body PSMA-PETscans were performed (33%). In addition, different PET radiotracers are used.
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Embark on a journey into the world of medical imaging as we unravel the distinctions between two powerful diagnostic tools—Computed Tomography (CT) scans and Positron Emission Tomography (PET) scans.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.
For patients with recurrent prostate cancer, PETscanning with 18F-flotufolastat led to major changes in treatment for 80 percent of patients and 75 percent of patients with a changed treatment focus to watchful waiting had negative scans, according to new research presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (..)
milla1cf Fri, 02/09/2024 - 09:17 February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before clinical symptoms arise, according to research published in the February issue of The Journal of Nuclear Medicine. The nonspecific control peptide demonstrated only low binding. “68
Centers for Medicare and Medicaid Services (CMS) has announced key changes to reimbursement that make advanced imaging more accessible, lifting its one-scan-per-patient restriction in 2023 and unbundling payment for high-cost diagnostic radiopharmaceuticals in 2024. Facilities wishing to appear on this list can fill out this brief survey.
A new technology, dubbed 'Augmented Whole-Body Scanning via Magnifying PET' (AWSM-PET), has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging
Amyloid PETscans provide in-vivo evidence of Alzheimer's disease (AD) pathology. However, due to their high cost and limited insurance coverage, they are not widely used in clinical settings outside of the VA Healthcare System.
mtaschetta-millane Sat, 06/24/2023 - 15:00 June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” ( AWSM-PET ) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
Recognizing the advent of beta amyloid-targeted therapies for the treatment of Alzheimer’s disease, the Centers for Medicare and Medicaid (CMS) has proposed eliminating coverage restrictions that limit amyloid positron emission tomography (PET) scans to clinical trial participants and one amyloid PETscan per lifetime.
LEADS participants receive a standard clinical evaluation and Magnetic Resonance Imaging ( MRI ) scanning as well as amyloid and tau PETscanning and fluid biomarker assessments on an annual basis. What Are the Clinical Implications? What Were Your Findings?
As one of the world’s authorities on prostate cancer treatment, Dr. Zelefsky has made major contributions to the field, shaping clinical practice guidelines and influencing treatment protocols worldwide.
This can look like a clinically significant finding on cancer imaging, including chest CTs, PETscans, mammography, and breast MRI. A small but significant number of people experience swollen lymph nodes as a side effect of receiving a COVID vaccine. … Continue reading →
The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B.,
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content